All due respect mate, you are expecting the wrong things here.
The readout of PFS on this trial is done and can not be changed at all. ORR is again very very unlikely to be changed, unless some of the patients get very late responding, which is extremely unlikely in this setting.
The things you can expect are overall survival and maybe biomarkers profiles in the cohort relating to survival profile.
Actually, the complete view of survival data is the one has never been released in TACTI002 and also the most important one in this late stage lung cancer trial.
Biomarker profile is maybe equivalent important as this will hint to the mechanism of EFTI working and will give a very good guiding to how well a phase III performance, which is pivotal for a big pharma to make decision.
Overnight Market report, page-1132
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.5¢ |
Change
0.005(1.72%) |
Mkt cap ! $428.5M | |||
| Open | High | Low | Value | Volume |
| 29.0¢ | 29.8¢ | 29.0¢ | $539.5K | 1.834M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 15 | 214062 | 29.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 29.5¢ | 469318 | 5 |
View Market Depth
| Last trade - 16.10pm 11/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |